Loading
PB
Provention Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Dec 2021.
Provention Bio, Inc.: what insiders have been doing
Provention Bio, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Provention Bio, Inc. The previous disclosure was published on 28 April 2023.
Since 2021, the database holds 3 purchases and 2 sales by insiders of the company.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€87,730
3 ops. · all time
Sell Volume
€26M
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$11.1M
Net income-US$97.8M-880.7% margin
Last declaration on 28 April 2023
Declarations23 total
15,567,497 sharesCommon StockSEC:0001062993-23-009669:0
7,500 sharesCommon StockSEC:0001493152-23-013919:0
10,000 sharesCommon StockSEC:0001493152-23-013910:0
70,000 sharesCommon StockSEC:0001493152-23-013906:0
2,570,050 sharesCommon StockSEC:0001493152-23-013916:0
73,000 sharesCommon StockSEC:0001493152-23-013907:0
202,314 shares0Common StockSEC:0001062993-23-009486:0
8,879,023 shares@ US$6.0064.8% of flowCommon StockSEC:0001062993-23-009310:0
10,000 shares0Common StockSEC:0001493152-23-012387:0
1,500,000 shares0Common StockSEC:0001493152-23-012403:0
3,000,000 shares0Common StockSEC:0001062993-23-008724:0
50,000 shares@ US$2.5059.8% of flowCommon StockSEC:0001493152-23-005076:0
4,500 shares@ US$10.0012100.0% of flowCommon StockSEC:0001493152-23-005078:0
50,000 shares@ US$2.5017.2% of flowCommon StockSEC:0001493152-23-005080:0
24,015 shares@ US$2.508.2% of flowCommon StockSEC:0001493152-23-002085:0
24,165 shares@ US$2.5028.8% of flowCommon StockSEC:0001493152-23-002086:0
3,000,000 shares@ US$9.4035.2% of flowCommon StockSEC:0001062993-23-001185:0
187,000 shares@ US$2.5065.0% of flowCommon StockSEC:0001493152-22-037133:0
10,674 shares@ US$2.503.7% of flowCommon StockSEC:0001493152-22-036789:0
1,568 shares@ US$2.500.5% of flowCommon StockSEC:0001493152-22-036596:0
5,201 shares@ US$6.492100.0% of flowCommon StockSEC:0001493152-21-030639:0
Canonical exit: 3 Mar 2022 (T+90)
3,750 shares@ US$6.66411.4% of flowCommon StockSEC:0001493152-21-030245:0
Canonical exit: 28 Feb 2022 (T+90)
5,550 shares@ US$7.2415.3% of flowCommon StockSEC:0001493152-21-030027:0
Canonical exit: 22 Feb 2022 (T+90)
23 of 23 declarations
About Provention Bio, Inc.
Provention Bio, Inc. was a U.S.-based clinical-stage biopharmaceutical company focused on intercepting and preventing immune-mediated diseases, with a particularly strong emphasis on type 1 diabetes. The company was incorporated in Delaware in 2016 and maintained its principal operational base in Red Bank, New Jersey, United States. For French-, Belgian-, and Swiss-based investors, Provention Bio represented a classic high-risk, high-catalyst biotechnology profile: valuation depended primarily on clinical development progress, regulatory milestones, and strategic transaction outcomes rather than on mature commercial scale. Before being acquired, the company was listed on the NASDAQ market in the United States, placing it squarely in the segment of growth-oriented biotech names where investor sentiment is highly sensitive to trial data and FDA decisions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai))
Its flagship asset was TZIELD (teplizumab-mzwv), a first-in-class anti-CD3 therapy designed to delay the onset of type 1 diabetes in selected high-risk patients. That asset gave Provention Bio a clearly differentiated market position: instead of competing in crowded symptomatic treatment markets, the company targeted early intervention in autoimmune disease progression. This focus on disease interception was central to the company’s identity and helped distinguish it from broader immunology or diabetes developers. Provention also pursued additional programs in immune-mediated and autoimmune indications, reinforcing its positioning as a science-led biotech platform built around prevention rather than conventional chronic-disease management. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Provention Bio’s strength lay in its narrow but potentially category-defining therapeutic thesis. The company’s differentiation stemmed from having a first-in-class asset with meaningful clinical and strategic appeal, rather than from breadth of revenue streams or geographic reach. That also meant concentration risk was high: a small number of programs had outsized influence on enterprise value, which is typical for NASDAQ-listed biotech companies at this stage. Its geographic footprint was primarily U.S.-based, with no indication of a broad global commercial infrastructure prior to acquisition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315222030280/R7.htm?utm_source=openai))
The most important recent corporate event was Sanofi’s acquisition of Provention Bio. On March 13, 2023, Sanofi announced an all-cash agreement to buy Provention Bio for $25.00 per share, implying an equity value of approximately $2.8 billion. The transaction was completed on April 27, 2023, and Provention Bio common stock ceased trading on NASDAQ that same day. As a result, Provention Bio is no longer an independently listed company; today it is best understood as a strategic acquisition that brought TZIELD into Sanofi’s portfolio. For investors reviewing historical SEC Form 4 insider activity, that means Provention Bio should be treated as a legacy listed issuer rather than an active public equity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/ex99-1.htm?utm_source=openai))
